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a b s t r a c t
The great majority of pharmacological investigations of 5-HT1A receptors’ reactivity has
been performed using racemic 8-OH-DPAT, therefore the biochemical as well as behavioral
profiles of both 8-OH-DPAT enantiomers are not circumstantiated. In the biochemical study
capability of racemic 8-OH-DPAT (0.05, 0.1 mg/kg s.c.) and its counterparts R-8-OH-DPAT
(0.05, 0.1 mg/kg s.c.) and S-8-OH-DPAT (0.05, 0.1 mg/kg s.c.) to influence 5-HT synthesis rate
in rats’ prefrontal cortex, hypothalamus, hippocampus and brainstem was evaluated by
HPLC/ED technique. Biochemical results are supported by the exhaustive computational
study of possible differences between R- and S-enantiomer toward the 5-HT1A receptor. A
reliable 3D model of the rat 5-HT1A receptor was constructed from the amino acid sequence
using the crystal structure of bovine rhodopsin as a structural template. The structure of the
receptor model was validated through docking studies and molecular dynamics simulations
that gave results consistent with experimental data. Docking studies and the dynamics of
ligand–receptor complexes emphasized different profiles of both enantiomers at the mole-
cular level. The results of both biochemical and computational studies confirmed that R-
enantiomer in contrast to S-8-OH-DPAT acts as full and potent agonist, whilst racemic form
may display similar pharmacological profile to R-8-OH-DPAT.
# 2006 Elsevier Inc. All rights reserved.
* Corresponding author. Tel.: +48 12 4214057; fax: +48 12 4214057.
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1. Introduction
8-OH-DPAT is a prototypical 5-HT1A receptor agonist [1].
During the last 25 years 8-OH-DPAT was extensively used for
pharmacological research to evoke variable biochemical
effects of 5-HT1A receptors’ activation: decrease of synthesis,
turnover [2] and release of 5-HT in different animals’ brain
regions [3] as well as to cause different behavioral responses:
hypothermia [4], hyperphagia [5], ‘‘5-HT1A syndrome’’ [6],
mydriasis [7], spontaneous tail-flicks [8], etc. 8-OH-DPAT is a
stereoselective compound. Generally, it is thought that R-8-
OH-DPAT acts as a full and potent 5-HT1A receptor agonist,
whereas S-8-OH-DPAT behaves as a partial agonist [9].
However, Hadrava et al. [10] reported that at postsynaptic 5-
HT1A receptors in hippocampus both isomers act as partial
agonists, because they antagonize suppressant effect of 5-HT.
AlthoughR- andS-8-OH-DPAThave similar binding affinities
to the 5-HT1A receptors in the rat hippocampus [11] as well as to
the cloned human 5-HT1A receptors [12], their efficacies are
different [9]. They behave differently in forskolin-stimulated
adenyl cyclase assay in rat hippocampal membranes, since R-
isomer could decrease the cAMP production to the same extent
as 5-HT itself, whereas its S-counterpart acts as a partial agonist
as it reduces cAMP levels to about 50% of the maximal reduction
induced by 5-HT [9]. R-8-OH-DPAT had also higher efficacy in
stimulation of human 5-HT1A receptor-mediated G protein
activation invitro (with a maximal effect of 90% relative to that of
5-HT) than S-isomer (57%), whereas racemic form (R,S-8-OH-
DPAT) displayed intermediate efficacy [12]. Hadrava et al. [10]
also reported, that R-enantiomer possess a two-fold greater
potency than its S-counterpart to activate 5-HT1A receptors
mediating suppression of hippocampus CA3 pyramidal neu-
rons firing. These findings are also consistent with data
suggesting that R-8-OH-DPAT has greater potency in inhibiting
the biosynthesis of 5-HT compared to S-isomer [1,13,14]. Also
differences in these compounds’ behavioral profiles in the
murine elevated plus-maze test [15], hypothermia [4,10] and
monosynaptic reflex in rats [16] may indicate different intrinsic
activity of both enantiomers at 5-HT1A receptors. It is also
noteworthy that enantioselective HPLC assay in rats’ biological
fluids produced evidence that the chirality of both stereo-
isomers is fully maintained in vivo [17]. No enantiomeric
interconversion was observed from R- to S-8-OH-DPAT or vice
versa, but the significant difference in clearance indicates a
stereoselective mechanism of elimination.
It is well known that 5-HT1A receptors located presynapti-
cally on the soma and dendrites of the 5-HT neurons of the
midbrain raphe nuclei, are involved in the effective inhibitory
control of serotonergic neurons activity [18–20]. Stimulation
of the somatodendritic 5-HT1A autoreceptors by a specific
agonist, e.g. 8-OH-DPAT causes a neuronal hyperpolarization,
decreases 5-HT cells firing rate, synthesis and turnover of
5-HT as well as release within raphe nuclei and subsequently
within serotonergic projection areas [21]. The biochemical
experiment has been focused on the assessment of any
possible difference at the level at presynaptic 5-HT1A receptors
between racemic 8-OH-DPAT and its active stereoisomer
R-8-OH-DPAT as well as S-8-OH-DPAT known to be partial
agonist. Therefore the capability of racemic 8-OH-DPAT and
its R- and S-stereoisomers to modify 5-HT synthesis rate was
determined by HPLC/ED technique by assay of 5-hydroxy-
tryptophan (L-5-HTP) accumulation after aromatic amino
acids decarboxylase inhibitor (NSD 1015) administration [22].
Molecular modeling techniques provide useful information
on structural and functional aspects of G-protein-coupled
receptors (GPCRs) and their interactions with ligands. GPCRs
are membrane spanning receptors that mediate most of their
intracellular actions through pathways involving activation of
G-proteins. The high resolution crystal structure of bovine
rhodopsin [23] provided for the first time a detailed atomic
description of a GPCR molecule and represents a solid basis for
modeling the structures of other rhodopsin-like GPCRs [24].
Such models have been extensively used to examine receptor
interactions with ligands, providing hypotheses concerning
structural determinants specifying high-affinity binding, selec-
tive binding or differences in binding of ligands [25]. The
combined use of molecular modeling approaches, site-directed
mutagenesis and biochemical studies gave detailed insight into
molecular mechanisms of receptor folding, receptor activation,
G-protein coupling, and regulation of GPCRs.
In the absence of 3D structures of 5-HT receptors, the
model of rat 5-HT1A receptor was constructed by comparative
modeling approach and used to simulate the molecular
dynamics of ligand–receptor complexes. The optimization of
transmembrane domain packing was carried out in the
presence of explicit methane molecules, mimicking the
non-polar environment of the membrane. The simulation
technique, where the membrane environment is replaced by
explicit methane molecules, is a fast and reliable method that
appears to reproduce several important characteristics of
membrane-embedded proteins [26–30]. A reliable 3D model of
the rat 5-HT1A receptor was used to study the interactions with
both enantiomers of 8-OH-DPAT, the estimation of their
binding affinities and free energies of binding to the receptor.
Moreover, the analysis of the possible differences in their
binding modes was performed.
Although fundamental difference between these chiral
compounds has already been indicated [13,31,32], the majority
of pharmacological research has been performed using
the racemic form of 8-OH-DPAT rather than its enantiomers.




MRN, median raphe nucleus
PFC, prefrontal cortex
TMH, transmembrane helix
The growing body of pharmacological reports emphasizes the
importance of using stereoselective compounds instead of the
racemic 8-OH-DPAT for biochemical and behavioral studies on
5-HT1A receptor function. To summarize, R-8-OH-DPAT dis-
plays greater efficacy than S-isomer in biochemical as well as
in behavioral testing, which clearly suggests stereoselectivity
in their intrinsic activities [9,14]. Therefore the purpose of the
present investigation was to gain insight into how the
enantiomers of 8-OH-DPAT exert their biological effects.
Molecular modeling studies were undertaken in order to
explain the phenomena of the stereo-structure-key to their
intrinsic activities and biochemical study was addressed to
investigate the possible difference between R- and S-isomer as
well as the racemate at the presynaptic 5-HT1A receptors’
level.
2. Materials and methods
2.1. Experimental procedures
2.1.1. Animals
Biochemical assay was conducted in rats, weighing 280–300 g.
Before the experiment the rats were housed in groups of six in
cages in a temperature-controlled room with free access to
food and water and maintained under a 12 h/12 h light/dark
cycle (light on 7.00). Each group of the experiment consisted of
six animals, with the exception of control-saline group (12
rats). Local Bioethical Committee approved the experiment
(permission #15/04, issued on 28 April 2004).
2.1.2. Drugs
NSD 1015 (m-hydroxybenzylhydrazine dihydrochloride), R-8-
OH-DPAT hydrobromide (R-8-hydroxy-2-(di-n-propylamino)-
tetralin), S-8-OH-DPAT hydrobromide and R,S-8-OH-DPAT
hydrobromide were purchased from Sigma Chemicals, St.
Louis, MO, USA. All substances were dissolved in 0.9% NaCl
solution (saline). Saline, R-, S- and R,S-8-OH-DPAT were
injected subcutaneously (s.c.), whilst NSD 1015 was adminis-
tered intraperitonally (i.p.). 8-OH-DPAT pharmacophores were
injected in the volume of 1 ml/kg, whilst NSD 1015 was
administered in 2 ml/kg. Doses of above compounds are
expressed as bases.
2.1.3. 5-HT synthesis rate
5-HT synthesis rate after aromatic amino acids decarboxylase
inhibitor (NSD 1015) injection was determined in prefrontal
cortex (PFC), hippocampus (CA), hypothalamus (HP) and
brainstem (BS) of rats by HPLC/ED technique [33]. 5-HT
synthesis rates were estimated after administration of saline,
full and potent 5-HT1A agonist R-8-OH-DPAT (0.05, 0.1 mg/kg),
partial 5-HT1A agonist S-8-OH-DPAT (0.05, 0.1 mg/kg) and
racemic 8-OH-DPAT (0.05, 0.1 mg/kg). All substances were
administered 15 min before NSD 1015 (100 mg/kg). Thirty
minutes after NSD 1015 administration animals were sacri-
ficed by decapitation and their PFC, CA, HP and BS were
immediately dissected on an ice-chilled plate and weighed.
The tissues were stored in deep freeze (70 8C) pending assay.
The tissue samples were homogenized in ice-cold 0.1 M
perchloric acid (HClO4) containing 0.05 mM ascorbic acid.
After centrifugation (15,000  g, 20 min), the supernatants
were filtered through 0.2 mm cellulose membranes (Titan-MSF
Microspin Filters, Lida Manufacturing Corp.) and were injected
into the HPLC system. Chromatography conditions—pump:
model 302 HPLC with manometric model 802C (Gilson, France);
precolumn: Hypersil BDS C18, 10 mm  4 mm, 3 mm (Thermo-
Quest, GB); column: Hypersil BDS C18, 250 mm  4 mm, 6 mm,
3 mm (ThermoQuest, GB); injector: model 2175 rheodyne inert
injector 20 ml loop (USA); flow rate: 0.7 ml/min; mobile phase:
75 mM NaH2PO42H2O (Avocado Res. Chem.), 1.7 mM 1-
octanosulfonic acid (Avocado Res. Chem.), 5 mM EDTA (Avo-
cado Res. Chem.), 100 ml triethylamine/1 l (Sigma), 9.5%
acetonitrile (Lab-Scan), pH 3.5 with phosphoric acid (Fluka).
Detector conditions—detector: model 141 electrochemical
detector (Gilson, France) with applied potential: +750 mV;
output voltage: 1 V; gain: 10 nA, filter settings 5 s. Levels of 5-
hydroxytryptophan (L-5-HTP) were expressed as pg/g of wet
tissue. 5-HT synthesis rates (pmol/g/h) were calculated
according to Carlsson et al. [22].
2.1.4. Data analysis
In chromatographic assay 5-HT synthesis rates (pmol/g/h)
were presented as means  S.E.M. and agonists treatment
effects were examined by analysis of variance (ANOVA one-
way) followed by Newman–Keul’s for post hoc analysis;
p < 0.05 was accepted as a statistically significant effect.
2.2. Molecular modeling
All calculations involving molecular mechanics (MM) energy
minimization and molecular dynamics (MD) simulation were
performed using Sander module of AMBER7 [34] and ff99 all-
atom force field [35]. A Coulombic potential on the grid of 1 Å
was calculated by LEaP (AMBER7) in order to place chloride
ions at positions of the highest electrostatic potential
around a protein molecule to neutralize it. To counteract
the charge of the entire receptor model bearing a ligand
molecule, a total of 14 chloride ions have been added, whereas
7 anions were required to exclusively neutralize the trans-
membrane domain. Bond constraints were imposed on all
bonds involving hydrogen atoms with the SHAKE algorithm
[36]. Long-range non-bonded interactions were truncated by
using a 12 Å cutoff (electrostatic and vdW). The time-step
length was 2 fs and the non-bonded pair list was updated
every 10 steps. At every 1000 steps the translational and
rotational motion was removed. The MD trajectories were
analyzed with Carnal monitoring the RMS deviation of Ca and
visually inspected with the VMD graphical software [37].
Docking procedures were carried out using AUTODOCK [38]
in a 20 Å  20 Å  20 Å cube surrounding the putative binding
site of the rat 5-HT1A receptor, allowing only conformational
freedom to the ligand. Each exploration procedure consisted of
100 independent runs of genetic algorithm (GA) using the
default options for the GA parameters.
2.2.1. Modeling of ligands
The initial structures of protonated R-8-OH-DPAT and 5-HT
were constructed using InsightII [39]. An initial structure of S-
8-OH-DPAT was constructed from the R-enantiomer by
reversion of the chiral center. MOPAC7 program [40] with
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AM1-BCC [41] set of parameters was used for geometry
optimization and charge calculation with the aid of Ante-
chamber [42]. In MD simulations the parameters were used in
conjunction with the general Amber force field (GAFF) [43].
2.2.2. Localization of transmembrane part
The sequence of rat 5-HT1A receptor [44] was retrieved from
the SwissProt sequence database [45]. The positions of seven
transmembrane helices in the receptor sequence as well as in
bovine rhodopsin were taken from the multiple sequence
alignment of 506 GPCRs sequences (class: A—rhodopsin like,
family: amine) provided by GPCRDB (information system for G-
protein-coupled receptors) [46].
2.2.3. Construction of seven-helix bundle
The helical bundle of the bovine rhodopsin [23] was used as a
structural template to build a model of the helical part of rat 5-
HT1A receptor by homology. The sequence of each helix was
aligned with that of the corresponding helix of rhodopsin.
Amino acids of rhodopsin were mutated to those of the rat 5-
HT1A receptor to construct an initial structure. The side chains
were built by SCWRL3, a rotamer library search method to
minimize the energy of steric clash [47].
2.2.4. Initial refinement of seven-helix bundle
The crude structures of transmembrane helices bundle
(without connecting loops and terminals) of 5-HT1A receptor
was refined by MM and MD simulation. Energy refinement was
done by 1000 cycles of steepest-descent minimization fol-
lowed by 1000 cycles of full-conjugate gradient minimization.
MD simulations were performed for backbone atoms con-
strained at their energy-minimized positions with a 10 kcal/
mol/Å2 force constant. The system was heated to 500 K for first
10 ps then gradually cooled to 100 K for 500 ps with long
temperature scaling. For the last 10 ps, the temperature was
decreased to 0 K and the model was further refined by
unconstrained energy minimization.
2.2.5. Identification of natural agonist binding site
The results from site-directed mutagenesis experiments
[48,49] were used as guidelines in the docking of 5-HT into
the central cavity of the 5-HT1A seven-helix bundle model. The
exploration was limited to the region containing the residues
experimentally known to be primarily involved in an agonist
binding. The position of 5-HT with the lowest energy of
binding reported by AUTODOCK was used in further simula-
tions. Subsequently, the transmembrane domain of the 5-
HT1A receptor containing 5-HT docked into the putative
binding site was subjected to optimization in a strongly
hydrophobic environment. The purpose of this action was to
obtain the optimized structure of seven-helix bundle of 5-HT1A
receptor in the active conformational state.
2.2.6. Optimization of the translational and rotational
orientation of the helices
The optimization of mutual orientation of seven transmem-
brane helices and the optimization of helical bends and kinks
were carried out in a strongly hydrophobic environment
formed by methane molecules. The structure of seven-helix
bundle of 5-HT1A receptor model bearing 5-HT molecule was
placed in a rectangular box containing 3591 methane
molecules. The size of the box was 73.05 Å  67.59 Å  55.30 Å
Å resulting in a volume of 273046.84 Å3 and a density of
approximately 0.5 g/cm3. The density of the methane box is
not the density observed in the hydrophobic core of the
membrane bilayer [50] due to the different equilibrium
distance between carbons in the methane box and in the
polycarbon chain of the lipids [26]. Moreover, the higher
density of the methane box may lead to short contacts
between molecules and thus extreme behavior of the system
[26]. Initially, the atoms of the receptor were kept fixed, while
the methane molecules were energy minimized (1000 cycles of
steepest-descent followed by 1000 cycles of conjugate gra-
dients), heated to 300 K in 100 ps and equilibrated for 200 ps.
Subsequently, the entire system was subjected to 500 ps of MD
simulation in 300 K at constant volume using particle mesh
Ewald method to evaluate electrostatic interactions [51]. A
dielectric constant of e = 1 has been used since an explicit
solvent produces the required dielectricity on its own accord.
To preserve the helical conformation of transmembrane
helices during molecular dynamics simulations, distance
restraints were applied between the backbone oxygen atom
of residue n and the backbone nitrogen atom of residues n + 4,
excluding prolines. It has been suggested that interhelical
hydrogen bonds in methane are stronger than in water and the
bond distances are shorter [26,52], therefore lower and upper
bounds of hydrogen bond restraints were set to 2.5 and 3.2 Å,
respectively. Every 1 ps the structures were collected for
analysis.
The total hydrophobic area (ASAH) of the receptor model





where ASAi is the accessible solvent area of ith residue, Hi the
standardized value of hydrophobicity for ith residue according
to Eisenberg scale of hydrophobicity for amino acids [53], and
N is the total number of residues. The accessible solvent area
of each residue was calculated using Surface module of Jackal
program [54].
2.2.7. Construction of loops and terminals
The conformations of N- and C-terminal as well as second
extracellular loop (ECL2) of 5-HT1A receptor were modeled
with the aid of MODELLER8v1 [55] using the corresponding
fragments of bovine rhodopsin [23] as structural templates.
The sequence alignments were done using ClustalW1.83 [56]
(Gap Opening Penalty: 10.00, Gap Extension Penalty: 0.20,
Delay divergent sequences: 30%, Protein weight matrix:
Gonnet series). The backbone structures of remaining loops
were built by RAPPER [57], an ab initio conformational sampling
method in dihedral space. For each loop the set of 1000
conformers was generated and the best conformation was
chosen based on RAPPER scoring function. The side chains of
terminals and loops were optimized using SCWRL3.
The third intracellular loop (ICL3) of the rat 5-HT1A receptor
consists of 116 amino acids, therefore this loop needed a
special treatment. The structure of ICL3 was predicted from
the amino acid sequence using ROBETTA (full-chain protein
structure prediction server) [58]. Additionally, the possibility of
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disulfide connectivity existence was examined for the ICL3
sequence by a disulfide bridges predictor DISULFIND [59].
Loops and terminals were connected to the helical bundle
and the entire 5-HT1A receptor model was subjected to an
energy refinement procedure.
2.2.8. Energy refinement of entire receptor model
The raw structure of 5-HT1A receptor model bearing 5-HT
molecule was energy-refined by MM and MD simulation. A
strongly hydrophobic environment formed by methane
molecules may unsuitably affect the conformation of loops
and terminals, therefore the environment was partially
compensated by setting a dielectric permeability e equal to
4r (where r is the inter-atomic distance in Å) in the absence of
an explicit solvent. During MD simulation loops and terminals
were allowed to move, whereas the atoms of TMHs as well as
5-HT were constrained with a 10 kcal/mol/Å2 force constant.
Minimization was carried out for 2000 steps before MD
simulation (1000 cycles of steepest-descent followed by 1000
cycles of conjugate gradients). For MD simulations the
molecule was heated to 450 K for 40 ps then gradually cooled
to 300 K for 100 ps. Subsequently, the entire system was
subjected to 1 ns of MD in 300 K to optimize the packing of
extra- and intercellular parts of 5-HT1A receptor model. The
atomic coordinate sets collected for the last 100 ps of
simulation were used to calculate an average structure, which
finally was energy-minimized in 2000 steps.
Site-directed mutagenesis studies of GPCRs have shown
that a pair of cysteines being highly conserved among all
GPCRs, forms a disulfide bond [60,61]. The disulfide bond
between C109 in TMH3 and C187 in ECL2 was present during all
calculations.
2.2.9. Docking of R- and S-8-OH-DPAT
The similar exploration procedure as described for the docking
of 5-HT was performed for R- and S-8-OH-DPAT separately and
the position of each ligand with the lowest energy of binding
was used in further simulations.
2.2.10. MD simulations of receptor–ligand complexes
To prevent unfolding and undesirable deformations of the
TMHs as well as to produce rigid helix body motions as
observed in experimental studies [62], distance restraints
O(n)–N(n + 4) were applied as described previously. Solvent
effects were included by using a distance-dependent dielectric
function (e = 4r) for the reasons given previously. A similar
strategy for constraining the transmembrane helices together
with a dielectric permeability of e = 4r has been used
previously during molecular dynamics simulations of G-
protein-coupled receptor models [63,64]. The coordinates
were saved at every 1 ps. MD simulations of receptor–ligand
complexes consisted of the following steps:
1. Initial unconstrained energy minimization procedure (1000
cycles of steepest-descent minimization followed by 1000
cycles of full-conjugate gradient minimization).
2. One hundred picoseconds of MD during which the tempera-
ture of the system was gradually raised from 0 to 300 K. The
receptor–ligand complex was constrained to its energy-
minimized structure by a weak potential of 0.5 kcal/mol/Å2.
3. Two hundred picoseconds of MD at constant temperature
during which the ligand was constrained to its energy-
minimized position by a potential of 0.05 kcal/mol/Å2,
allowing the protein to accommodate the ligand. To prevent
the premature conformational changes of the receptor until
the system became fully equilibrated, the two terminal Ca
atoms of each TMH were constrained with a 0.05 kcal/mol/
Å2 force constant.
4. Production run including two different protocols:
4.1. One nanosecond of unconstrained MD at 300 K.
4.2. One nanosecond of MD at 300 K during which the
ligand was constrained by a very weak potential of
0.005 kcal/mol/Å2. The results obtained for this proto-
col are denoted ‘ligand-constrained’.
5. The atomic coordinate sets collected for the last 100 ps of
production run were used to calculate an average structure,
which finally was energy-minimized in 2000 steps (1000
cycles of steepest-descent minimization followed by 1000
cycles of full-conjugate gradient minimization).
2.2.11. Estimation of affinity value and free energy of binding
The estimation of the affinity value (Ki) as well as the free
energy of binding (Ebind) of R- and S-8-OH-DPAT toward the rat
5-HT1A receptor was done using AUTODOCK facility. The
energy-minimized average structure of each receptor–ligand
complex after MD simulations was used for the redocking of
the ligand into the central cavity of the 5-HT1A receptor model.
Cluster analysis was performed and structurally similar multi-
member clusters were outputted. A cluster including the
positions of ligand corresponding to the one present in the
energy-minimized average structure of receptor–ligand com-
plex was identified based on the reference RMSD values and
further used in the calculation of standard deviation and the
mean value of estimated affinity and free energy of binding.
3. Results and discussion
3.1. Molecular modeling
3.1.1. 5-HT1A receptor modeling
The process of the rat 5-HT1A receptor model construction
started from identifying membrane spanning helices based on
the multiple sequence alignment and further modeling of the
transmembrane domain. The start and end positions of TMHs
in the model were found to be: F33-I61 (TMH1), V70-L99
(TMH2), G105-T139 (TMH3), P150-L173 (TMH4), D192-R223
(TMH5), E340-P369 (TMH6), and L380-K405 (TMH7). The helical
part of the rat 5-HT1A receptor was modeled by homology,
using bovine rhodopsin as a structural template.
Building a protein model always requires several theore-
tical assumptions and methodological approximations.
Therefore to validate the 5-HT1A receptor model, the fully
automated docking of the natural ligand 5-HT was under-
taken. If the structure of the putative binding site is correct,
then a docking study should be able to detect the proper
binding mode for high-affinity ligands, reflecting most of the
experimentally known favorable interactions [48,49]. The 5-
HT was correctly positioned into the inner part of the seven-
helix bundle and the fundamental ligand–protein interactions
b i o c h e m i c a l p h a r m a c o l o g y 7 2 ( 2 0 0 6 ) 4 9 8 – 5 1 1502
suggested by the mutagenesis data were detected. 5-HT
formed an ionic interaction with its protonated nitrogen
and the negatively charged carboxy terminus of the highly
conserved D116 in TMH3. Moreover 5-hydroxy group of 5-HT
was placed in a favorable position to form hydrogen bonds
with S199 and T200 in TMH5. Finally, an aromatic stacking
between the aromatic rings of 5-HT, F361 and F362 was
observed.
Since the conformation of a-helices located in hydrophilic
environments, such as water, differs from the conformation of
a-helices located in hydrophobic environments, such as the
cell membrane [50], the transmembrane domain containing 5-
HT ligand located in the putative binding site was subjected to
the optimization in a strongly hydrophobic environment. The
optimization was carried out by immersing the protein into a
hydrophobic environment formed by methane molecules and
performed rigid body molecular dynamics. Explicit methane
molecules were supposed to mimic an environment that is not
able to form hydrogen bonds with the peptide carbonyl oxygen
of a helix. A significant change in the conformation of the a-
helix depending whether the peptide bond is exposed to bulk
of water or to the lipid membrane has already been studied by
molecular dynamics simulations in the box of methane as well
as by surveying crystal structures of membrane proteins [26].
Furthermore, it has been proved that the simulation in the
methane environment reproduces the dihedral angles profile
of the Pro kink observed in the analysis of crystal structures,
indicating that the methane box can reproduce the conforma-
tional behavior of helical deformations as well [26]. Similar
conditions have been employed to mimic the membrane
environment in molecular dynamics simulations of the
potassium channel [27], thyrotropin receptor [28] as well as
individual TMHs of the CCR5 [29] and 5-HT1A [30] receptors.
Time-dependent changes in RMS displacement of Ca
atoms as well as in the total hydrophobic surface area (ASAH)
of seven-helix bundle during 500 ps of MD simulation in the
presence of explicit methane molecules are shown in Fig. 1.
Both parameters reached an equilibrium state after circa
200 ps, fluctuating around a constant mean value. This is
sufficient to indicate successful optimization of the transla-
tional and rotational orientation of the helices in strongly
hydrophobic environment.
The loops and terminal fragments were connected to the
transmembrane domain and the entire model was further
energy refined by MD simulation. Since no disulfide
connectivity existence was detected for the ICL3 sequence,
only one disulfide bond between C109 in TMH3 and C187 in
ECL2 was present during all simulations. The overall
structure of energy-refined 5-HT1A receptor model is shown
in Fig. 2. Both extra- and intracellular domain adopted a
compact structure with the mainly negative electrostatic
potentials observed around the extracellular parts and
mainly positive around the intracellular parts. It was
suggested that the negatively charged area outside the
extracellular parts initiates agonist binding to the 5-HT1A
receptor by electrostatic interactions with the protonated
basic nitrogen of a ligand [64]. Moreover, the predicted
binding site (shown in Fig. 2 as a molecular surface) was
found to be in excellent agreement with the residues
determined experimentally to be involved in binding.
The R- and S-8-OH-DPAT were docked into the putative
active site of 5-HT1A receptor and 1 ns of unconstrained MD
simulations were carried out. Additional MD simulations of
both ligand–receptor complexes with the ligands constrained
by a very weak potential were performed in order to
investigate the trajectories devoid of the substantial variations
of ligands geometries.
3.1.2. Conformational analyses of ligands
The initial structures of protonated R- and S-8-OH-DPAT
obtained by the geometry optimization differ with respect to
the position of the basic nitrogen atom relative to the
tetraline ring. Differences in the overall conformations occur
in the orientations of the di-n-propylamino moieties as a
consequence of the opposite chiralities of the C2 carbon. In
R-enantiomer the basic nitrogen atom is positioned equa-
torial at the tetraline ring, whereas in S the nitrogen atom is
oriented in an axial fashion. Moreover, the C1–C2–N–H
torsion angle calculated for R- and S-8-OH-DPAT was found
to be 172.38 and 40.38, respectively. These results indicate
that only the R-enantiomer satisfies well the criteria
proposed for a bioactive conformation [65]. The analysis of
trajectories revealed that the geometry of R-8-OH-DPAT was
maintained during 1 ns of unconstrained MD simulations of
ligand–receptor complex, whereas during unconstrained MD
simulation of the S-8-OH-DPAT–5-HT1A complex, an inter-
esting distortion in the ligand conformation was observed.
After 620 ps the nitrogen atom moved to the position
equatorial at the tetraline ring, through an interme-
diate form appeared in a short time at 570–620 ps (Fig. 3).
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Fig. 1 – The a-carbon RMSD from the starting structure and
the total hydrophobic surface area (ASAH) plotted as a
function of simulation time for the 5-HT1A transmembrane
domain in methane.
The conformation of S-enantiomer bearing equatorial amino
substituent requires the energy penalty of 1.88 kcal/mol.
Along the last 380 ps of unconstrained MD of both R- and S-8-
OH-DPAT–5-HT1A complexes, the hydroxy substituent, the
aromatic nuclei and the protonated nitrogen atoms were
oriented in a similar fashion and strongly resembled the
pharmacophore model. It is noteworthy that the conforma-
tion of S-8-OH-DPAT bearing equatorial amino substituent
was not observed during docking exploration procedure
before MD simulation.
3.1.3. Binding pockets for R- and S-8-OH-DPAT
The amino acids remaining in the close vicinity of R- and S-8-
OH-DPAT bound to the rat 5-HT1A receptor in the energy-
minimized average complexes after MD simulations are
shown in Table 1. Moreover, the positions of side chains
surrounding both enantiomers are depicted in Fig. 4. The
predicted binding sites were found to be in excellent
agreement with the residues determined experimentally to
be involved in binding [48,49].
All G-protein-coupled monoaminergic receptors contain a
highly conserved aspartic acid residue at similar positions in
TMH3, corresponding to D116 in the 5-HT1A receptor. Site-
directed mutagenesis studies have revealed that mutation of
this residue in D2 receptor to an uncharged one completely
abolishes the binding of both receptor agonists and antago-
nists [66], strongly suggesting that the negatively charged
carboxy terminus of the aspartic acid is involved in forming a
reinforced electrostatic interaction with the protonated,
positively charged nitrogen atom of natural and synthetic
receptor ligands. Although the overall orientations of R- and S-
8-OH-DPAT within the binding site were not identical, both
enantiomers formed a reinforced electrostatic interaction
with their protonated nitrogens and D116.
Furthermore, the hydroxyl group present in the chemical
structure of many neurotransmitters seems to hydrogen
bond a series of Ser/Thr residues in TMH5 [67]. A serine (S199)
and threonine (T200) residue in TMH5 of the 5-HT1A receptor
are both capable of forming hydrogen bonds with the 5-
hydroxy group of 5-HT. The 5-hydroxy substituent of 5-HT
may act as a hydrogen bond acceptor, since the methoxy
analogues of 5-HT and hydroxy-containing synthetic 5-HT1A
receptor agonists are usually equipotent. The importance of
T200 for 5-HT binding was supported by site-directed
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Fig. 2 – Overall structure of the rat 5-HT1A receptor model. Seven TMHs are presented as ribbons, whereas the predicted
binding site is shown as a molecular surface (dark grey). Left panel: view along the plane of cell membrane. Right panel:
transmembrane domain as viewed from the extracellular side.
Fig. 3 – The average RMSD from the optimized structure for
S-8-OH-DPAT during MD simulation of the ligand–receptor
complex. The distortion energies (DE1 = 0.48 kcal/mol and
DE2 = 1.04 kcal/mol) were calculated for energy-minimized
average structures of the ligand (shown in sticks
representation) along 0–570, 570–620 and 620–1000 ps.
mutagenesis studies [49]. A bifurcated hydrogen bond was
observed between the hydroxy substituent of both 8-OH-
DPAT enantiomers and side chains of S199 and T200, thus
confirming the role of these amino acids during the binding
process.
Additionally, the binding sites of both enantiomers of 8-
OH-DPAT also included residues of TMH6 and TMH7 that
experimental studies on dopamine D2 [68] and b2-adrenergic
[69] receptors have demonstrated to be ligand accessible. The
mutation studies have shown that phenylalanine residues in
TMH6 are crucial for ligand binding [70]. An edge-to-face
aromatic stacking between the aromatic ring of both enantio-
mers of 8-OH-DPAT and F361 and F362 were maintained
during the unconstrained MD simulations, presumably con-
tributing to the affinity by hydrophobic interactions. Such
interactions between S-8-OH-DPAT and aromatic residues of
TMH6 were abolished by imposing the constraints on the
ligand during the MD simulation.
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Table 1 – Residues within 5 Å of R- and S-8-OH-DPAT bound to the rat 5-HT1A receptor model
Ligand Receptor domain Amino acid residue
R-8-OH-DPAT TMH3 F112, I113, D116, V117, C120, T121
TMH4 P171
ECL2 W175, T188, I189, S190
TMH5 Y195, T196, S199, T200, A203, F204
TMH6 F361, F362, V364, A365, L368, P369
ECL3 M377
TMH7 I385, N386, Y390
R-8-OH-DPAT (ligand-constrained) TMH2 Y96
TMH3 F112, I113, D116, V117, C120, T121
ECL2 W175, I189, S190
TMH5 Y195, T196, S199, T200, A203, F204
TMH6 F361, F362, V364, A365, L368, P369
ECL3 M377
TMH7 G382, I385, N386, Y390
S-8-OH-DPAT TMH2 Y96
TMH3 F112, I113, D116, V117, C120, T121
TMH4 P171
ECL2 W175, T188, I189
TMH5 T196, S199, T200, A203, F204
TMH6 F361, F362, V364, A365, P369
ECL3 M377
TMH7 I385, N386, Y390
S-8-OH-DPAT (ligand-constrained) TMH3 I113, D116, V117, C120, T121
TMH4 I167
ECL2 I189, S190
TMH5 T196, S199, T200, A203
TMH6 W358, F361, F362, V364, A365, L368, P369
ECL3 M377
TMH7 G382, I385, N386
The residues within 3 Å are distinguished in bold.
Fig. 4 – Close view on the binding pocket for R-8-OH-DPAT (A) and S-8-OH-DPAT (B) in energy-minimized average structures
of the ligand–receptor complexes after unconstrained (black) and ligand-constrained (grey) MD simulations.
Finally, the hydrophobic interactions were detected
between the di-n-propyl substituents of both enantiomers
and the side chains of residues localized in ECL2 (Table 1). Site-
directed mutagenesis experiments and molecular modeling
studies have demonstrated that certain residues in ECL2 are
important for binding of ligands to the dopamine D2 [71], a1A
adrenergic [72] and adenosine receptors [73]. A direct contact
between ligands and residues in ECL2 is possible due to the
presence of a disulfide bridge formed between C109 in TMH3
and C187 in ECL2 [60,61], which would covalently attach the
ECL2 in physical proximity to the ligand binding site [73]. In
addition, the ECL2 was proposed to enter into the binding site
crevice of biogenic amine receptors and form a lid over the
bound ligand [25]. Interestingly, the single residue of ECL3
constantly remaining in the vicinity of a ligand was observed
in all MD trajectories of ligand–receptor complexes (Table 1).
An indirect role of ECLs in the formation of a channel for ligand
entrance to the primary binding site within helical bundle was
suggested [74].
During the unconstrained as well as ligand-constrained MD
trajectories, both enantiomers of 8-OH-DPAT remained con-
stantly trapped in a cavity localized in the inner part of the
seven-helix bundle of 5-HT1A receptor. However, as can be
seen in Fig. 4, even in corresponding sites with each
enantiomer anchored by the same receptor residues, they
did not have identical binding modes. In addition, the
constraints imposed on the S-enantiomer significantly
affected the overall conformation of the binding site.
3.1.4. Estimated free energy of binding and affinity value of R-
and S-8-OH-DPAT toward 5-HT1A receptor
The estimated values of free energy of binding (Ebind) as well as
the values of affinity (Ki) of both enantiomers toward the rat 5-
HT1A receptor are presented in Fig. 5. For each enantiomer the
conformation resulting from both unconstrained as well as
ligand-constrained MD simulation was taken into account
during the redocking of the ligand into the central cavity of the
receptor model. The results seem to be in qualitative
agreement with experiments. Thus, it was reported that in
vitro binding affinities of R- and S-enantiomer toward 5-HT1A
receptor are 4.1 and 6.1 nM, respectively [11] as well as toward
the cloned 5-HT1A receptor (0.47, 0.64 and 0.58 nM, for R-, S-
and R,S-8-OH-DPAT, respectively) [12]. Moreover, the intro-
duction of constraints on a ligand during MD simulations of
ligand–receptor complexes produced significant changes in
the affinity of S-enantiomer toward the receptor. A con-
strained S-8-OH-DPAT further displayed significantly lower
affinity for the 5-HT1A receptor (41.37  5.23 nM) than uncon-
strained (12.71  1.54 nM), whereas the affinities analogically
estimated for R-enantiomer were found to be comparable
(2.17  0.31 and 1.39  0.14 nM, respectively). Additionally, the
values of the free energy of binding to the 5-HT1A receptor
were found to be similar for both enantiomers (Fig. 5). The
conformational analysis of the distortion of S-8-OH-DPAT
geometry during unconstrained MD simulation (Fig. 3)
revealed that the orientation bearing equatorial amino
substituent can be adopted. This may explain the similarities
of the free energy of binding and affinity of R- and S-8-OH-
DPAT toward the 5-HT1A receptor reported by experiments
[11,12].
3.1.5. Structural differences between ligand–receptor
complexes
A significant difference between the energy-minimized
average structures of receptor–ligand complexes after MD
simulations was observed. The RMS displacement of recep-
tors’ Ca atoms calculated for the R-8-OH-DPAT–5-HT1A versus
S-8-OH-DPAT–5-HT1A after unconstrained MD was found to be
3.533 Å (Fig. 6). The corresponding value of RMSD-Ca calcu-
lated exclusively for part of the intracellular domain including
ICL2, ICL3 and C-terminal tail is 4.721 Å. Since this domain is
known to be responsible for G-protein coupling [75], such
structural differences may contribute to the efficacy differ-
ences for both 8-OH-DPAT enantiomers, reported in biochem-
ical [9,31] as well as behavioral experiments [4,10,15,16].
Although the efficacy of a ligand toward the receptor
cannot be estimated quantitatively using the presented
model, the structural differences found in the intracellular
domain after MD simulations of the 5-HT1A receptor
complexed with R- and S-8-OH-DPAT suggest substantial
differences in G-protein coupling. Therefore it may be
concluded that the intrinsic activities of R- and S-enantio-
mer toward 5-HT1A receptor are different. It is also
noteworthy that the differences in the intracellular domain
conformation were observed after both unconstrained as
well as ligand-constrained MD simulations. In addition, the
constraints imposed on both enantiomers significantly
affected the overall conformation of the receptor as well
as the TMHs domain.
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Fig. 5 – Estimated affinities (Ki) toward the 5-HT1A receptor
and the values of the free energy of binding (Ebind) for R-
and S-8-OH-DPAT.
3.2. Biochemical experiment
3.2.1. 5-HT synthesis rate in discrete parts of the brain
Activation of 5-HT1A receptors by specific agonists, e.g.
prototypical 8-OH-DPAT [1], reveals inhibitory action on
serotonergic cell firing and consequently decreases synthesis
of 5-HT in raphe nuclei and serotonergic projection areas
[20,21]. In chromatographic assay of 5-HT synthesis rate
relatively low doses of 8-OH-DPAT pharmacophores were
used. However, they were chosen to act exclusively via 5-HT1A
autoreceptors and to reveal any possible subtle difference
between these compounds’ biochemical profiles on the level at
presynaptic receptors. R-8-OH-DPAT (0.05, 0.1 mg/kg) as well
as R,S-8-OH-DPAT (0.05, 0.1 mg/kg) caused a significant,
similar reduction of 5-HT synthesis rate in CA ( p < 0.02 in
comparison to saline-treated rats, Fig. 7A), PFC (p < 0.02,
Fig. 7B) and BS (p < 0.05, Fig. 7C), hence 0.05 mg/kg was a
sufficient dose for both compounds to attenuate 5-HT
synthesis rate and higher dose did not intensify inhibitory
effect on 5-HT synthesis in above brain’s structures. S-8-OH-
DPAT (0.05, 0.1 mg/kg) was unable to significantly attenuate 5-
HT synthesis rate in the mentioned structures, although in
brainstem statistical significance was almost reached for S-8-
OH-DPAT 0.1 mg/kg (p = 0.06). Results derived from CA, PFC
and BS confirmed that R-8-OH-DPAT acts as full and potent
agonist, whereas S-form, even as a partial agonist, is unable to
affect 5-HT synthesis rate in both doses tested. Simulta-
neously racemic 8-OH-DPAT is equally potent as R-form in 5-
HT synthesis rate inhibition in above brain regions.
Administration of R-8-OH-DPAT 0.05 mg/kg caused also
significant reduction of 5-HT synthesis rate in the HP (p < 0.02
in comparison to saline-treated animals, Fig. 7D), whereas
racemic 8-OH-DPAT in both doses failed to decrease 5-HT
synthesis rate in that brain region. Interestingly, the difference
between R-8-OH-DPAT 0.05 mg/kg and racemic 8-OH-DPAT
appeared in brain region which is known to be innervated
mainly by serotonergic projections from MRN, in opposite to
PFC innervated mainly by ascending projections from DRN, BS,
which contains both midbrain raphe nuclei and CA innervated
by DRN and MRN [76]. Such a finding suggests that R,S-8-OH-
DPAT at those doses is insufficient to decrease 5-HT synthesis
rates in HP, since it was established that 5-HT1A receptors
located on MRN 5-HT neurons are less sensitive to specific
agonist than DRN 5-HT1A receptors [77,78]. Therefore it cannot
be excluded that lower doses of both stereoisomers could
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Fig. 7 – 5-HT synthesis rates (pmol/g/h, expressed as
means W S.E.M., n = 6–12) after saline, R-8-OH-DPAT (0.05,
0.1 mg/kg), S-8-OH-DPAT (0.05, 0.1 mg/kg) or R,S-8-OH-
DPAT (0.05, 0.1 mg/kg) injection in hippocampus (A),
prefrontal cortex (B), brainstem (C) and hypothalamus (D)
of rat’s brain. 5-HT synthesis rates were estimated by
chromatographic assay of L-5-HTP level after NSD 1015
(100 mg/kg) administration; *p < 0.05, **p < 0.02, #p = 0.06
compared to saline-treated rats by analysis of variance
(ANOVA one-way) followed by Newman–Keul’s for post
hoc analysis.
Fig. 6 – RMS differences of the entire receptor and
individual domains (TM: transmembrane domain, IC: part
of the intracellular domain including ICL2, ICL3 and C-
terminal) calculated for energy-minimized average
structures of the receptor complexed with R- and S-8-OH-
DPAT [denoted as (R)-5-HT1A and (S)-5-HT1A, respectively].
reveal such difference also in brain regions innervated by DRN.
It could not also be ruled out that higher doses of both
enantiomers would have had more robust effects, however
there were no trends in this direction. However, S-8-OH-DPAT
0.1 mg/kg was able to significantly inhibit 5-HT synthesis rate in
HP (p < 0.05), whereas R-8-OH-DPAT 0.1 mg/kg failed to evoke
such effect in this area (Fig. 7D). ThereforeS-8-OH-DPAT 0.1 mg/
kg induced attenuation of 5-HT synthesis rate in HP argues
against assumption that R,S-8-OH-DPAT does not contain
sufficient amount of the active R-isomer capable to evoke such
effect in HP. Since 5-HT synthesis rate attenuation is related to
5-HT1A receptor activation, non-specific action of S-8-OH-DPAT
can also be excluded. However, the intrinsic activity and
potency of 5-HT1A receptor agonist are dependent on receptor
density and may vary for different second messenger systems.
It is known that 5-HT1A receptor can interact with several
different signal transduction pathways and several G-proteins
present in different concentrations in various brain regions and
thus may cause varying ability to couple the receptor to a
particular effector protein. This may explain the large variation
in the same agonist potency [79]. The molecular modeling part
of this study also revealed structural differences in the
intracellular domain responsible for G-protein coupling after
MD simulations of the 5-HT1A receptor complexed with R- and
S-8-OH-DPAT. It may suggest substantial differences in G-
protein coupling, which may finally lead to differences in the
intrinsic activities of R- and S-enantiomer toward 5-HT1A
receptor in various brain structures, depending on the effector
system, 5-HT1A receptors density as well as different transduc-
tion system [80]. Thus it may be concluded that in HP S-8-OH-
DPAT can act even as full agonist. On the other hand S-8-OH-
DPAT was completely unable to affect 5-HT synthesis rate in
brain regions innervated by DRN serotonergic neurons PFC and
CA innervated by both DRN and MRN. It argues against
hypothesis that even a weak partial agonist could suppress
serotonergic transmission via these receptors due to higher 5-
HT1A receptors’ reserve in DRN [81].
Previous biochemical findings are mostly compatible with
the results presented in this paper, since in electrophysiolo-
gical measurements S-isomer had about three-fold lower
potency than R-isomer to inhibit electrical activity of DRN
serotonergic neurons, whereas R,S-8-OH-DPAT showed inter-
mediate activity [12]. In the microdialysis study conducted by
Yoshitake and Kehr [4] R-enantiomer (0.3 mg/kg) was about
twice more potent in reducing the extracellular 5-HT level in
ventral hippocampus than its S-counterpart (0.3 mg/kg);
however, R-8-OH-DPAT administered at the same dose as
racemate reduced 5-HT level only by additional 6–10% more
than the latter. Similar findings were found in hypothermic
study by the above authors, since significant differences
between the hypothermic effects of racemate or R-8-OH-DPAT
compared to S-isomer at both doses tested (0.1, 0.3 mg/kg)
were reported. The racemate and its R-counterpart showed
almost identical profile of hypothermic effect. S-Isomer was
about 50% less potent than R and R,S to induce hypothermia.
Yoshitake and Kehr [4] therefore concluded that R and R,S are
almost equally potent in reduction of body temperature and 5-
HT release in ventral hippocampus, which is consistent with
our experiment since R- and R,S-8-OH-DPAT had equal
potencies in inhibiting 5-HT synthesis rate in CA, PFC and
BS. Such lack of the difference between R-isomer and
racemate results probably from the relatively high doses of
R,S-8-OH-DPAT used, because it presumably contains suffi-
cient amount of active, R-form capable to evoke the
biochemical as well as hypothermic effect.
4. Conclusions
The results of the present study emphasized the stereoselec-
tivity of 8-OH-DPAT toward the serotonin 5-HT1A receptor. The
molecular modeling strategy allowed a reliable 3D model of the
rat 5-HT1A receptor to be constructed from the amino acid
sequence using the crystal structure of bovine rhodopsin as a
structural template. The structure of the receptor model was
validated through docking studies and molecular dynamics
simulations that gave results consistent with experimental
data. Docking studies and the dynamics of ligand–receptor
complexes revealed the distortion of S-8-OH-DPAT geometry
during unconstrained MD simulation. The conformation of S-
enantiomer bearing equatorial amino substituent may explain
the similarities of the free energy of binding and affinity of R-
and S-8-OH-DPAT toward the 5-HT1A receptor reported by
autoradiographic experiments. However, a significant differ-
ence between the energy-minimized average structures of
receptor–ligand complexes (especially within the part of the
domain responsible for G-protein coupling) after MD simula-
tions may contribute to the efficacy differences for both 8-OH-
DPAT enantiomers. Based on the presented results it might be
possibly explained that R-8-OH-DPAT acts as a full, potent
agonist, whereas S-8-OH-DPAT requires a structural distortion
to the active potent form of this compound. Racemic 8-OH-
DPAT could in fact behave as a potent or less potent agonist
according to the dose used and the brain region being
investigated due to the greater sensitivity of 5-HT1A receptors
located in DRN to 8-OH-DPAT. Therefore according to previous
findings and the results presented in this paper the biochemical
as well as behavioral effects evoked by the racemic form can be
similar or slightly less significant than elicited by pure R-
enantiomer. On the other hand it should be emphasized that at
the level at presynaptic 5-HT1A receptors, such difference could
occur, especially in brain areas innervated by MRN. The similar
effects of R-enantiomer and racemate observed in PFC, CA and
BS in the biochemical experiment might result from still high
dose of R,S-8-OH-DPAT used and/or the capability of racemate
to act as a full potent R-isomer, since its S-counterpart is able to
distort to the structural-active pharmacophore. However, even
assuming the equal potencies ofR- and R,S-8-OH-DPAT in brain
structures innervatedbyDRN, itmay bebetter toavoid using the
racemic form in areas less sensitive to 5-HT1A agonist.
Although S-8-OH-DPAT was reported to have partial
agonistic property at 5-HT1A receptors, it was unable at both
doses tested to significantly inhibit 5-HT synthesis rate in all
examined brain areas, with exception of HP. The results may
indicate the different sensitivity of particular brain’s regions to
5-HT1A agonist, especially in area innervated by MRN
serotonergic projections, since S-8-OH-DPAT was able to
evoke inhibitory effect on 5-HT synthesis in HP. The results
of both biochemical and computational studies confirmed that
R-enantiomer in contrast to S-8-OH-DPAT acts as a full and
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potent agonist, whilst the racemic form may display similar
pharmacological profile to R-8-OH-DPAT.
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